Clinical Policy: AbobotulinumtoxinA (Dysport)
Reference Number: ERX.SPMN.217
Effective Date: 01/17
Last Review Date:

See Important Reminder at the end of this policy for important regulatory and legal information.

Policy/Criteria
It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that abobotulinumtoxinA (Dysport®) is medically necessary when one of the following criteria are met:

I. Initial Approval Criteria
   A. Cervical Dystonia or Limb Spasticity (must meet all):
      1. Prescribed by or in consultation with a/an neurologist, orthopedist, or physiatrist;
      2. Diagnosis of one of the following:
         a. Cervical dystonia;
         b. Upper limb spasticity;
         c. Lower limb spasticity;
      3. Prescribed dose of Dysport does not exceed 1000 units per single treatment session.

      Approval duration: 12 weeks (single treatment session)

   B. Other diagnoses/indications:
      1. Refer to ERX.SPMN.16 - Global Biopharm Policy if requested indication is non-cosmetic.

II. Continued Approval
   A. Cervical Dystonia or Limb Spasticity (must meet all):
      1. Currently receiving medication via health plan benefit or member has previously met all initial approval criteria;
      2. Prescribed dose of Dysport does not exceed 1000 units per single treatment session;
      3. It has been at least 12 weeks since the last injection of Dysport.

      Approval duration: 12 weeks (single treatment session)

   B. Other diagnoses/indications (must meet either 1 or 2):
      1. Currently receiving medication via health plan benefit and documentation supports positive response to therapy; or
      2. Refer to ERX.SPMN.16 - Global Biopharm Policy if requested indication is non-cosmetic.

Background
Description/Mechanism of Action:
AbobotulinumtoxinA is a purified neurotoxin type A complex produced by fermentation of the bacterium Clostridium botulinum. It inhibits release of the neurotransmitter, acetylcholine, from
peripheral cholinergic nerve endings. This accounts for the therapeutic utility of the toxin in diseases characterized by excessive efferent activity in motor nerves. Recovery of transmission occurs gradually as the neuromuscular junction recovers and as new nerve endings are formed.

*FDA Approved Indication(s):*
Dysport is an acetylcholine release inhibitor and neuromuscular blocking agent/intramuscular injection indicated for:
- Treatment of adults with cervical dystonia;
- Temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults < 65 years of age;
- Treatment of upper limb spasticity in adults to decrease the severity of increased muscle tone in elbow flexors, wrist flexors and finger flexors;
- Lower limb spasticity in pediatric patients 2 years of age and older.

**Coding Implications**
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0586</td>
<td>Injection, abobotulinumtoxinA, 5 units</td>
</tr>
</tbody>
</table>

**Reviews, Revisions, and Approvals**

<table>
<thead>
<tr>
<th>Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/16</td>
<td>01/17</td>
</tr>
</tbody>
</table>

**References**

**Important Reminder**
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.
This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2016 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.